Chronic Spontaneous Urticaria Clinical Trials Update 2026: Phase-Wise Pipeline Status, Drug Profiles, and Key Developers | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly
(Albany, New York) – October 22, 2026: As per DelveInsight’s assessment, globally, Chronic Spontaneous Urticaria pipeline constitutes 20+ key companies continuously working towards developing 25+ Chronic Spontaneous Urticaria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. “Chronic Spontaneous Urticaria Pipeline Insight, 2026“ report by DelveInsight outlines





